Pfizer's ADCETRIS approval is expected to have limited impact on ZYNLONTA's market position. ZYNLONTA's peak opportunity in indolent lymphomas is estimated at $100-200 million.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ...
